Q2 EPS Estimates for Kymera Therapeutics Raised by B. Riley

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Equities research analysts at B. Riley upped their Q2 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a note issued to investors on Monday, May 12th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of ($1.01) for the quarter, up from their previous forecast of ($1.02). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.85) EPS, FY2026 earnings at ($3.88) EPS, FY2027 earnings at ($3.88) EPS and FY2028 earnings at ($3.80) EPS.

A number of other analysts have also commented on the company. Bank of America dropped their price target on Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a report on Monday. Guggenheim restated a “buy” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a research note on Monday. HC Wainwright boosted their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Stephens restated an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, UBS Group lowered their target price on Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average price target of $55.27.

Kymera Therapeutics Trading Up 0.9%

Shares of Kymera Therapeutics stock opened at $30.02 on Wednesday. The business’s fifty day simple moving average is $29.42 and its 200 day simple moving average is $37.18. The firm has a market capitalization of $1.95 billion, a P/E ratio of -12.83 and a beta of 2.18. Kymera Therapeutics has a 12 month low of $19.45 and a 12 month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Kymera Therapeutics’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same period last year, the company posted ($0.69) earnings per share.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KYMR. Wellington Management Group LLP lifted its stake in shares of Kymera Therapeutics by 13.0% in the 1st quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company’s stock valued at $164,134,000 after acquiring an additional 689,547 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Kymera Therapeutics by 14.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock valued at $207,184,000 after acquiring an additional 650,000 shares during the last quarter. Deerfield Management Company L.P. Series C bought a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $23,856,000. Boxer Capital Management LLC bought a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $17,098,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Kymera Therapeutics by 2,397.9% in the 4th quarter. Janus Henderson Group PLC now owns 377,384 shares of the company’s stock valued at $15,197,000 after acquiring an additional 362,276 shares during the last quarter.

Insider Transactions at Kymera Therapeutics

In other news, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company’s stock, valued at $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,659 shares of company stock worth $324,567. 16.01% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.